Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
Aktis is targeting a valuation of up to $945.4 million in the IPO.
Related Post
Panama Supreme Court Voids CK Hutchison Port Deals, Canal Operations in Limbo
Panama City/Hong Kong: Panama's Supreme Court has annulled key port contracts held by a subsidiary…
Warren Demands Huang and Lutnick Testify on Trump’s Nvidia China Chip Move
Democratic Senator Elizabeth Warren called on Thursday for Nvidia CEO Jensen Huang and Commerce Department…
Pinterest plunges 21%, posts second-worst day ever as tariffs drag on ad revenue
Pinterest shares plummeted 21% on Wednesday after lackluster third-quarter earnings as advertising took a hit from…